Kimberly Blackwell

All filings by Kimberly Blackwell on record concern Zentalis Pharmaceuticals, Inc., in the capacity of board member. We count 13 filings; the first trade dates from 4 June 2021 and the latest from 1 February 2024.

On the open market, the record shows 1 purchase worth €48k and 4 sales worth €282k. Taken together, the sales exceed the purchases by €234k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 share grants and 4 option exercises.

Most recently, on 5 February 2024, the filings show a share grant worth €223k in Zentalis Pharmaceuticals, Inc. The clock since the last published purchase (13 November 2023) now reads 1,092 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.